featured
Safety and Efficacy of Short Oral Regimens for the Treatment of Rifampicin-Resistant Tuberculosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial
Lancet Respir Med 2023 Nov 15;[EPub Ahead of Print], BT Nyang'wa, C Berry, E Kazounis, I Motta, N Parpieva, Z Tigay, R Moodliar, M Dodd, V Solodovnikova, I Liverko, S Rajaram, M Rassool, T McHugh, M Spigelman, DA Moore, K Ritmeijer, P du Cros, K FieldingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.